drugset / Trial / NCT01304316
Dose-Escalation Safety and Pharmacokinetic Study of K305
Phase 2
Completed
12 enrolled
St. Renatus, LLC
Ground Zero Pharmaceuticals · collabRho, Inc. · collab
NaSingle-groupOpen-labelSupportive care
Summary
The purpose of this study is to determine the pharmacokinetics/pharmacodynamics and safety of a nasal spray containing the anesthetic drug tetracaine in combination with oxymetazoline
Timeline
- Start
- 2010-09
- Primary completion
- 2010-11
- Completion
- 2010-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Oxymetazoline | Other / unclassified | 0.3 mg | Intranasal |
| Subject | Oxymetazoline | Other / unclassified | 0.6 mg | Intranasal |
| Subject | tetracaine | Other / unclassified | 18 mg | Intranasal |
| Subject | tetracaine | Other / unclassified | 36 mg | Intranasal |
Indications
No indication recorded.